Clinical Trials Logo

Hemodialysis Complication clinical trials

View clinical trials related to Hemodialysis Complication.

Filter by:

NCT ID: NCT05874557 Not yet recruiting - Clinical trials for Hemodialysis Complication

A Study of Compound Amino Acid Capsule on Maintenance Hemodialysis Patients

Start date: June 2023
Phase:
Study type: Observational

The goal of this retrospective cohort study is to investigate the effects of compound amino acid capsule on nutrition, calcium and phosphorus metabolism in maintenance hemodialysis(MHD) patients. The main questions it aims to answer are: 1. Can compound amino acid capsule improve the nutritional status of MHD patients? 2. Can compound amino acid capsule help to correct the calcium and phosphorus metabolism imbalance of MHD patients? 3. Is compound amino acid capsule safe for MHD patients? We will collect the medical history and laboratory data of MHD patients who regularly took compound amino acid capsule for 9 months or did not use the same preparation in previous medical experience. We focus on the difference of serum albumin level between the treatment group and the control group within 9 months, as well as prealbumin, hemoglobin, ferritin, calcium, phosphorus, 1,25-OH 2-D3 and intact parathyroid hormone (iPTH).

NCT ID: NCT05874219 Completed - Clinical trials for Hemodialysis Complication

Mupirocin 2% Ointment Vs Spray Antibiotics on Temporary Hemodialysis Catheter

Start date: April 10, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

In dialysis centers, many patients are undergoing hemodialysis simultaneously, which facilitates the spread of microorganisms by direct or indirect contact through the devices, equipment, surface contact, and hands of health profession Over time, catheters are prone to higher rates of infection, thrombosis, and central venous stenosis, it has also been shown that catheters are an independent (of infection) inflammatory stressor and lead to increased morbidity . Catheters are aptly referred to as a bacterial highway, and a biofilm formation around the catheter is often the breeding ground of bacteria and fungi, which can easily spread to the bloodstream Infectious complications are the most serious with regards to patient morbidity and mortality. The incidence could be from 3.8 to5.5 episodes per 1000 days Migration of micro-organism along the external surface of the catheter is probably the most common route of infection through skin and represents 58% .HD catheter has biofilm formation on their surfaces and this serves as a good reservoir for micro-organisms Most patients with end stage renal disease (ESRD) starting hemodialysis through hemodialysis catheter about 9 % in Egypt and most of them require several hemodialysis catheters before maturation of arterio -venous fistula and even after stopping it.

NCT ID: NCT05872984 Completed - Clinical trials for Hemodialysis Complication

Evaluation of Total Blood Volume Measurement During Dialysis on the Incidence of Intradialytic Hypotension

Start date: July 9, 2020
Phase: N/A
Study type: Interventional

Establishing the euvolemic state in hemodialysis patients -the so called "dry weight"- is an important clinical conundrum in every nephrologist's daily practice. Underestimation of dry weight (with excessive ultrafiltration) results in dialysis-induced hypotension. Currently used methods to establish dry weight, including clinical assessment, bio-impedance spectroscopy and online relative blood volume (RBV) measurements, all have their limitations. RBV measurement reflects changes in blood volume during dialysis without providing any information about the initial hydration status, or the initial absolute blood volume (ABV). Recently, researchers proposed a new method to calculate ABV, by using the principle of dilution-indicator with RBV measurement. In a small cohort study they identified a total blood volume threshold of 65 millilitres per kilogram dry weight predicting for intra-dialytic hypotension associated symptoms. The goal of current clinical trial is to re-investigate the accuracy of the above-described method and to confirm the hypothesis of a critical threshold of 65 ml blood volume per kg dry weight in haemodialysis patients. Researchers will compare adjustment of dry weight based on the ABV measurement with standard care to see if dialysis-induced hypotension will be reduced.

NCT ID: NCT05837988 Not yet recruiting - Clinical trials for Hemodialysis Complication

Construction of Symptom Network in Maintenance Hemodialysis Patients

Start date: May 8, 2023
Phase:
Study type: Observational

Through a cross-sectional questionnaire survey, a general information questionnaire and Dialysis Frequency, Severity, and Symptom Burden Index were used to investigate the frequency, severity, and degree of symptom distress in MHD patients, and to analyze the differences in symptom distress status between long and short dialysis age MHD patients. Using the R 4.2.2 software qgraph package, construct symptom networks for MHD patients of long and short dialysis age through network analysis. Analyze network centrality indicators, including intensity, closeness centrality, and mediation centrality, to identify core symptoms and compare if there are any differences between the two groups, aiming to lay the foundation for precise and efficient phased symptom management.

NCT ID: NCT05817799 Recruiting - Clinical trials for Hemodialysis Complication

Impact of Hemodialysis on Plasma Carnitine Levels in Patients With End Stage Renal Disease

Start date: January 1, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

OBJECTIVES - To assess the levels of plasma carnitine in controls and hemodialysis patients. - To give supplementary L-carnitine to study subjects for a duration of 5months. - To compare the values of plasma carnitine before and after L carnitine supplementation. - To assess the role of carnitine supplementation on biochemical and clinical parameters.

NCT ID: NCT05809765 Completed - Clinical trials for Hemodialysis Complication

Effect of Triflow Breathing Training

Start date: May 16, 2020
Phase: N/A
Study type: Interventional

This study aims to explore whether an 8-week Triflow breath training program reduced the anxiety levels and improved the heart rate variability and quality of life of patients receiving hemodialysis. To investigate the effect of the triflow respiration training on the improvement of heart rate variability, anxiety, and the quality of life in hemodialysis patients.

NCT ID: NCT05743998 Completed - Clinical trials for Chronic Kidney Diseases

Inactivity and Quality of Life in Dialysis Patients

Start date: February 28, 2023
Phase:
Study type: Observational

The goal of this observational study is to compare hemodialysis and peritoneal dialysis patients. The main questions it mains to answer are: - What is the level of physical activity in hemodialysis and peritoneal dialysis patients? - What is the level of quality of life of hemodialysis and peritoneal dialysis patients? - Is there any relation between inactivity and quality of life in hemodialysis and peritoneal dialysis patients? Participants will answer 2 questionnaires and will do some functional tests.

NCT ID: NCT05722496 Completed - Clinical trials for Hemodialysis Complication

Difference Between Interval and Continous Intradialytic Exercise on Functional Capacity in Hemodialysis Patient

Start date: January 3, 2023
Phase: N/A
Study type: Interventional

The goal of this study is to find out the effect of interval versus continous intradialytic training on muscle quality index and functional capacity in Hemodialysis patients. The main question it aims to answer is: Does interval versus continous intradialytic training have an effect on muscle quality index and functional capacity in hemodialysis patients? Patients will be assigned randomly by computerized block randomization into two groups:Group (A): 30 patients will participate in 8 weeks of aerobic exercise in the form of high intensity interval training (HIIT) intradialytic pedaling exercise plus hemodialysis (3 sessions per week).Group (B): 30 patients will participate in 8 weeks of aerobic exercise in the form of moderate intensity continous training (MICT) intradialytic pedaling exercise plus hemodialysis (3 sessions per week) . primary and secondary variables will be measured before starting treatment and after completion (after 2 months )

NCT ID: NCT05708248 Not yet recruiting - Clinical trials for Hemodialysis Complication

Effect of Pentoxifylline on Anemia in Hemodialysis Patients

Start date: February 2023
Phase: N/A
Study type: Interventional

The primary goal of this clinical trial is to evaluate the promoting effect of pentoxifylline on anemia correction in hemodialysis patients, and involvement of the hypoxia-inducible factor-2 alpha. While, the secondary aim is to evaluate the effect of pentoxifylline on inflammation, hepcidin and other markers of iron homeostasis in these patients. Participants in this trial will be selected to be age and sex ratio matched and will be randomly assigned into two groups. Patients in group I will receive their regular doses of erythropoietin stimulating agents and other routine treatments plus 400 mg pentoxifylline tablets twice daily with meals for 6 months. While, patients in group II will receive their regular doses of erythropoietin stimulating agents and other routine treatments.

NCT ID: NCT05586867 Recruiting - Clinical trials for Hemodialysis Complication

Study of Markers of Iron Metabolism and Their Relationship With Phosphocalcic and Hepatic Metabolism and Inflammation in Hemodialysis Patients

MARMEFE
Start date: December 1, 2021
Phase:
Study type: Observational

From a scientific point of view and for publication purposes, it therefore seems important to study the metabolism of iron and in particular to define its conditions of absorption, metabolism, elimination and storage in the body at course of advanced renal failure. The study will follow the evolution of hormones regulating iron metabolism and put into perspective their links with phosphocalcic and hepatic metabolisms as well as inflammation in hemodialysis patients. The main objective of this program is to study the evolution of hepcidin and erythroferrone levels in hemodialysis patients. These two biomarkers regulating iron metabolism are not performed routinely in dialysis centers and are not listed in the nomenclature.